Biohaven (BHVN) Other Non-Current Liabilities (2021 - 2026)
Biohaven (BHVN) reported Other Non-Current Liabilities of $4.6 million for Q1 2026, down 94.84% on a YoY basis from $88.3 million in Q1 2025, and down 0.59% sequentially from $4.6 million in Q4 2025.
Biohaven (BHVN) Other Non-Current Liabilities (2021 - 2026) Analysis & Trends
Biohaven (BHVN) has 6 years of Other Non-Current Liabilities data on file, last reported at $4.6 million in Q1 2026.
- For the quarter ending Q1 2026, Other Non-Current Liabilities fell 94.84% year-over-year to $4.6 million; the trailing twelve-month figure through Mar 2026 stood at $4.6 million (down 94.84% YoY), and the FY2025 full-year result was $4.6 million, down 1.72% from the prior year.
- Other Non-Current Liabilities declined to $4.6 million in Q1 2026, from $4.6 million in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $268.3 million in Q3 2025 to a low of $2.2 million in Q4 2023.
- A 5-year average of $43.9 million and a median of $4.6 million in 2026 frame the typical range for Other Non-Current Liabilities.
- Across the five-year window, Other Non-Current Liabilities surged 5849.32% in 2025 and sank 94.84% in 2026, its largest moves.
- Tracing BHVN's Other Non-Current Liabilities over 5 years: stood at $2.4 million in 2022, then retreated by 6.85% to $2.2 million in 2023, then soared by 107.71% to $4.7 million in 2024, then declined by 1.72% to $4.6 million in 2025, then dropped by 0.59% to $4.6 million in 2026.
- Business Quant data shows BHVN's Other Non-Current Liabilities at $4.6 million in Q1 2026, $4.6 million in Q4 2025, and $268.3 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Biohaven | 2.16 Bn | 1.81 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.56 Mn |
| Dec 31, 2025 | 4.58 Mn |
| Sep 30, 2025 | 268.27 Mn |
| Jun 30, 2025 | 257.07 Mn |
| Mar 31, 2025 | 88.32 Mn |
| Dec 31, 2024 | 4.66 Mn |
| Sep 30, 2024 | 4.59 Mn |
| Jun 30, 2024 | 4.32 Mn |
| Mar 31, 2024 | 3.41 Mn |
| Dec 31, 2023 | 2.25 Mn |
| Sep 30, 2023 | 2.27 Mn |
| Jun 30, 2023 | 2.52 Mn |
| Mar 31, 2023 | 2.50 Mn |
| Dec 31, 2022 | 2.41 Mn |
| Sep 30, 2022 | 7.00 Mn |
| Dec 31, 2021 | 2.64 Mn |